CPS1 and Hyperammonemia: This leads to the accumulation of toxic metabolites such as 2-propyl-4-pentenoic acid (4-en-VPA), which impair hepatic function and inhibit carbamoyl phosphate synthetase I (CPS-I), contributing to complications including CNS depression, hyperammonemia, and hepatotoxicity [4].